Inarigivir soproxil Inhibitor

Solid. Powder

98.35%

Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent

703.62

DMSO: 102mg/mL (144.96mM)
(<1mg/ml refers to the product slightly soluble or insoluble)

C25H34N7O13PS

CO[C@@H]1[C@H](OP(=O)(OC[C@H]2O[C@H](C[C@@H]2O)n2cnc3c(N)ncnc23)SCOC(=O)OC(C)C)[C@@H](CO)O[C@H]1n1ccc(=O)[nH]c1=O

942123-43-5

HCV 1a/1b: ic50 2.2/1.0uM (EC50)
HCV

Inarigivir soproxil is shown to inhibit HCV replication and the range of inhibition is comparable between genotypes 1a and 1b. Inarigivir soproxil is an oral modulator of innate immunity that is believed to act via the activation of the RIG-I and NOD2 pathways. Inarigivir soproxil demonstrates pan-genotypic antiviral activity against HCV. Inarigivir soproxil is active against DAA-resistant HCV variants. SB 9200 has broad-spectrum antiviral activity against RNA viruses including hepatitis C virus (HCV), norovirus, respiratory syncytial virus and influenza and has demonstrated activity against hepatitis B virus (HBV)[1].

Microbiology&virology; Proteases/Proteasome